株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮内膜癌治療薬の世界市場:2018年〜2022年

Global Endometrial Cancer Therapeutics Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 707382
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.99円で換算しております。
Back to Top
子宮内膜癌治療薬の世界市場:2018年〜2022年 Global Endometrial Cancer Therapeutics Market 2018-2022
出版日: 2018年09月18日 ページ情報: 英文 110 Pages
概要

子宮内膜癌について

子宮内膜癌は、子宮癌の一種であり、女性の子宮の内層(子宮内膜)を形成する細胞の層から始まります。閉経中のエストロゲン補充療法のような、プロゲステロンによる拮抗のない状態での子宮内膜エストロゲン曝露は、女性の子宮内膜癌発症リスクの上昇と関連しています。

Technavioのアナリストは、2018年から2022年の間に、世界の子宮内膜癌治療法市場が5.17%のCAGRで成長すると予測しています。

当レポートでは、世界の子宮内膜癌治療法市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模および予測(2017-2022年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第7章 パイプライン

第8章 市場セグメンテーション:製品別

  • セグメンテーション:製品別(2017-2022年)
  • 比較:製品別
  • 化学療法
  • ホルモン療法
  • 市場機会:製品別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション(2017-2022年)
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • 免疫療法
  • オーダーメード医療
  • 医薬品開発パイプラインにおける小分子の増加

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

第16章 付録

  • 略語のリスト
図表
  • Exhibit 01: Parent market
  • Exhibit 02: Global uterine cancer therapeutics market segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global endometrial cancer therapeutics market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 09: Global endometrial cancer therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase 2017-2018
  • Exhibit 19: Key clinical trials
  • Exhibit 20: Global endometrial cancer therapeutics market - Market share by product 2017-2022 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Chemotherapy - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Chemotherapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Hormone therapy - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 25: Hormone therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global endometrial cancer therapeutics market - Market share by geography 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in Americas
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: CELGENE - Overview
  • Exhibit 46: CELGENE - Business segments
  • Exhibit 47: CELGENE - Organizational developments
  • Exhibit 48: CELGENE - Geographic focus
  • Exhibit 49: CELGENE - Key offerings
  • Exhibit 50: CELGENE - Key customers
  • Exhibit 51: Janssen Pharmaceuticals - Overview
  • Exhibit 52: Janssen Pharmaceuticals - Business segments
  • Exhibit 53: Janssen Pharmaceuticals - Organizational developments
  • Exhibit 54: Janssen Pharmaceuticals - Geographic focus
  • Exhibit 55: Janssen Pharmaceuticals - Segment focus
  • Exhibit 56: Janssen Pharmaceuticals - Key offerings
  • Exhibit 57: Janssen Pharmaceuticals - Key customers
  • Exhibit 58: Novartis - Overview
  • Exhibit 59: Novartis - Business segments
  • Exhibit 60: Novartis - Organizational developments
  • Exhibit 61: Novartis - Geographic focus
  • Exhibit 62: Novartis - Segment focus
  • Exhibit 63: Novartis - Key offerings
  • Exhibit 64: Novartis - Key customers
  • Exhibit 65: Pfizer - Overview
  • Exhibit 66: Pfizer - Business segments
  • Exhibit 67: Pfizer - Organizational developments
  • Exhibit 68: Pfizer - Geographic focus
  • Exhibit 69: Pfizer - Segment focus
  • Exhibit 70: Pfizer - Key offerings
  • Exhibit 71: Pfizer - Key customers
  • Exhibit 72: Teva Pharmaceutical Industries - Overview
  • Exhibit 73: Teva Pharmaceutical Industries - Business segments
  • Exhibit 74: Teva Pharmaceutical Industries - Organizational developments
  • Exhibit 75: Teva Pharmaceutical Industries - Geographic focus
  • Exhibit 76: Teva Pharmaceutical Industries - Segment focus
  • Exhibit 77: Teva Pharmaceutical Industries - Key offerings
  • Exhibit 78: Teva Pharmaceutical Industries - Key customers
目次
Product Code: IRTNTR23738

About Endometrial Cancer

Endometrial cancer is a type of uterine cancer, which begins in the layer of cells that form the lining (endometrium) of the uterus of women. Unopposed endometrial estrogen exposure such as estrogen replacement therapy during menopause is associated with increased risk of developing endometrial cancer among women.

Technavio's analysts forecast the Global Endometrial Cancer Therapeutics Market to grow at a CAGR of 5.17% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the endometrial cancer therapeutics market. To calculate the market size, the report considers the revenue generated by treatment of endometrial cancer across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Endometrial Cancer Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • Market driver
  • Increasing prevalence of endometrial cancer
  • For a full, detailed list, view our report

Market challenge

  • High cost associated with treatment
  • For a full, detailed list, view our report

Market trend

  • Immune therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2017-2022
  • Hormone therapy - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Immune therapy
  • Personalized medicine
  • Increase in small molecules in drug development pipeline

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

PART 16: APPENDIX

  • List of abbreviations
Back to Top